Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

Phase 4Active Not RecruitingNCT05949008

University of California, Los Angeles150 enrolled

Overview

Metformin is a drug used to treat patients with diabetes. The aim of this study is to examine the effect of Metformin along with a low-calorie diet on obese and/or overweight adults with an increased waist measurement. In addition, the study also aims to look at the effect of the drug vs. placebo on quality of life and physical activity.

Obesity is a growing epidemic in the United States. Weight gain is associated with an increased risk of developing life-threatening conditions such as high blood pressure or diabetes. Therefore, there is great interest in developing non-invasive treatments to help combat obesity. Currently, there are only few weight-loss drugs available for the treatment of obesity. In the more recent past, GLP-1 analogues (a type of non-insulin medication used to treat patients with diabetes) are being promoted as a new strategy to lose weight without major side effects however, with high costs and challenging supply chain issues. This is a double-blinded, randomized study. This means that participants will be assigned to one of two groups. Participants will have a 1:1 chance of being assigned to receive either the study drug or a placebo (a capsule that does not contain the active ingredients). This assignment will be determined by chance. The process is similar to drawing cards or picking straws. This means your assignment to one of the groups is based on chance and not a medical decision made by the study doctor. In addition, neither participants nor the investigators will know what groups participants have been assigned to. During this study, your participation will last up to 26 weeks (including screen) with a total of 8 clinic visits. Participants will undergo a total of 5 blood draws, blood samples will be taken at screen baseline and weeks 8, 16 and 24.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

150

Conditions

NIDDM Obesity

Interventions

Metformin Extended Release (ER) Oral TabletDRUG

Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.

PlaceboDRUG

Matching placebo will be provided as 1000 mg capsules

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, age ≥ 18 years at the time of signing informed consent. * Body Mass Index (BMI) ≥ 27 kg/m2 * Waist circumference \>40" for men, and \>35" for women Exclusion Criteria: * A self-reported change in body weight \> 5 kg (11 lbs) within 90 days before screening irrespective of medical records * Diagnosed with T2D (HbA1c \>7.5 (53 mmol/mol) * Current use of insulin or oral medication of metformin, SU, SGLT2i, glitazone, DPP4 or GLP-1 agonist injections as single agent therapy or combination oral agents. * Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of \< 45 mL/min/1.73 m2 (\< 60 ml/min/1.73 m2 in subjects treated with SGLT2i) according to CKDEPI creatinine equation as defined by KDIGO 201242 by the central laboratory at screening * History of thyroid disease, but not taking medication or medication dosage changed one or more times over last 6 months (History of thyroid disease and on a stable dose of prescription medication for 6 months or longer is acceptable). * History or lactic acidosis * Liver problems * Congestive heart failure * History of alcoholism * Recent surgery * Heart attack, severe infection or stroke * Any unstable medical conditions or terminal diagnosis * Pregnancy or lactation * Allergy and intolerance to metformin

Locations (1)

UCLA Center for Human Nutrition

Los Angeles, California, United States

Outcomes

Primary Outcomes

Number of participants who achieve body weight reduction ≥5% from baseline

Percent change in body weight reduction ≥5% from baseline (week 0) to week 24.

Time frame: 24 Weeks

Change in total body weight from baseline

Percent change in total body weight (TBW) from baseline (week 0) to week 24 in body weight.

Time frame: 24 Weeks

Secondary Outcomes

Change in total Body Mass Index (BMI) from baseline

Change from baseline (week 0) to week 24 in: BMI

Time frame: 24 Weeks

Percent change in body composition from baseline

Change from baseline (week 0) to week 24 - Body composition will be measured using a bioelectrical impedance analysis (BIA) scale. Measurements will include fat mass (kg), lean mass (kg), and body fat percentage. Data will be summarized as mean change from baseline to study endpoint for each group.

Time frame: 24 weeks

Change in waist circumference from baseline

Change from baseline (week 0) to week 24 in:Waist circumference (cm)

Time frame: 24 weeks

Change in insulin sensitivity from baseline

Insulin sensitivity will be assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), calculated from fasting glucose and fasting insulin levels. QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using fasting glucose and insulin. The outcome will be reported as the change in QUICKI from baseline to Week 24.

Time frame: 24 Weeks

Change in fasting blood lipids from baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.